Logo

GBIO

Generation Bio Co.

GBIO

Generation Bio Co. • NASDAQ
$5.33 ▲ 0.57% (+0.03)
Market Cap $35.91 M
52w High $15.30
52w Low $3.00
Dividend Yield 0%
P/E -0.57
Volume 5.62K
Outstanding Shares 6.74M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.594M ▲ $21.688M ▼ $-5.52M ▲ -346.299% ▲ $-0.82 ▲ $-4.116M ▲
Q2-2025 $765K ▼ $23.681M ▼ $-20.923M ▼ -2.735K% ▼ $-3.12 ▼ $-21.268M ▼
Q1-2025 $8.723M ▲ $25.329M ▼ $-14.802M ▲ -169.689% ▲ $-2.21 ▲ $-14.332M ▲
Q4-2024 $4.188M ▼ $27.751M ▲ $-21.382M ▼ -510.554% ▼ $-3.2 ▼ $-18.786M ▼
Q3-2024 $7.554M $25.438M $-15.313M -202.714% $-2.29 $-15.535M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $89.622M ▼ $121.896M ▼ $71.336M ▼ $50.56M ▼
Q2-2025 $141.363M ▼ $179.432M ▼ $125.331M ▼ $54.101M ▼
Q1-2025 $157.559M ▼ $201.348M ▼ $128.016M ▼ $73.332M ▼
Q4-2024 $185.223M ▲ $231.197M ▼ $144.993M ▲ $86.204M ▼
Q3-2024 $184.77M $248.784M $144.342M $104.442M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.52M ▲ $-52.68M ▼ $25.528M ▲ $-2K ▼ $-27.154M ▼ $-52.68M ▼
Q2-2025 $-20.923M ▼ $-16.828M ▲ $14.951M ▲ $80K ▲ $-1.797M ▲ $-17.287M ▲
Q1-2025 $-14.802M ▲ $-28.36M ▼ $2.957M ▼ $-7K ▼ $-25.41M ▼ $-28.606M ▼
Q4-2024 $-21.382M ▼ $-15.784M ▲ $70.284M ▲ $144K ▲ $54.644M ▲ $-16.162M ▲
Q3-2024 $-15.313M $-19.547M $12.708M $-3K $-6.842M $-19.638M

Five-Year Company Overview

Income Statement

Income Statement Generation Bio is still essentially a pre‑revenue biotech. Reported revenue has been minimal and does not yet reflect a commercial product, more likely small collaboration or service income. The company has posted steady operating losses every year, reflecting ongoing research, platform development, and overhead without offsetting product sales. The scale of losses has been relatively consistent over time, which signals disciplined but sustained spending to advance the technology rather than sudden cost blow‑outs. Overall, the income statement looks typical for an early‑stage platform biotech: science‑heavy, revenue‑light, and dependent on external capital rather than internal profits.

Balance Sheet

Balance Sheet The balance sheet shows a company that once had a strong cash and asset base but has been drawing it down over time to fund development. Total assets and cash have gradually declined, and shareholder equity has eroded as losses accumulate. Debt, which was initially absent, has appeared and grown to a modest level, adding some financial leverage but also future repayment obligations. Equity is still positive, but the cushion is noticeably smaller than a few years ago. This profile suggests a company that has used a meaningful chunk of its initial capital and now has less balance‑sheet flexibility than earlier in its public life.

Cash Flow

Cash Flow Cash flows underline the classic early‑stage biotech pattern: money consistently flowing out to support research and operations, with no offsetting commercial inflows. Operating cash flow has been negative every year, and free cash flow closely tracks this, since capital spending needs are modest. The burn appears somewhat more controlled in the most recent periods, but it remains material relative to the reduced cash balance. This means the company’s future development pace and independence are likely tied to securing new funding, partnerships, or strategic transactions rather than self‑funding from operations.

Competitive Edge

Competitive Edge Scientifically, Generation Bio occupies a differentiated niche. Its cell‑targeted lipid nanoparticle platform aims to deliver genetic medicines specifically to T cells, with the goal of precisely modulating the immune system rather than broadly suppressing it. Early preclinical data and the partnership with a major mRNA player like Moderna provide external validation and suggest a meaningful technological moat if the approach works in humans. At the same time, the company is small, preclinical, and operating in a highly competitive field where many better‑funded players are also pursuing gene and cell‑directed therapies. Financial strain and strategic uncertainty could weaken its competitive stance if larger rivals move faster into the same space, or conversely make it an attractive technology acquisition target.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Generation Bio’s story. The company is developing non‑viral, potentially redosable genetic medicines using a platform designed to selectively target T cells with siRNA payloads. This could open up previously “undruggable” intracellular targets and enable more tailored treatments for autoimmune and inflammatory diseases. The platform appears modular, meaning it could, in principle, support a pipeline of different programs once validated. However, the science is still at the preclinical stage, and recent restructuring indicates that R&D priorities and timelines may be shifting, possibly narrowing the active pipeline. Future value creation hinges on translating the promising lab and animal data into clear lead programs, human‑ready candidates, and further proof that the technology is safe, effective, and scalable.

Summary

Generation Bio is a classic high‑science, high‑risk early‑stage biotech. Financially, it has minimal revenue, steady operating losses, shrinking cash and equity, and ongoing cash burn that will likely require new capital or strategic deals. Strategically, it holds a potentially powerful and differentiated platform for T‑cell‑targeted genetic medicines, with encouraging preclinical evidence and a notable collaboration that supports its scientific credibility. The main tension is between the strength of the technology and the weakness of the balance sheet: the platform could be valuable if successfully developed, but the company’s ability to fund and control that journey on its own is uncertain. Outcomes may depend heavily on partnerships, strategic alternatives, and the pace at which its leading programs are clarified and advanced toward the clinic.

NEWS

November 5, 2025 · 4:05 PM UTC

Generation Bio Announces Third Quarter 2025 Financial Results

Read more

October 22, 2025 · 4:05 PM UTC

Generation Bio Announces CEO Transition

Read more